Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Studies torquetenovirus levels during immunotherapy in kidney cancer patients

Observes torquetenovirus levels in adults with kidney cancer receiving first-line immunotherapy.

Plain-language title generated from the registry record
Registry title: Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma

Key facts

Where
Rome, ItalySee the site

Where in Italy

  • Regina Elena National Cancer InstituteRome, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Regina Elena Cancer Institute
Trial code
NCT07018037
Record updated
5 June 2026
Original description
The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.Read full original descriptionShow less

Pilot Study to Describe the Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma

The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.

Inclusion: Patients over 18 years of age; Histological diagnosis of clear cell renal cell carcinoma; Evidence of advanced or metastatic disease; Patients diagnosed with metastatic clear cell renal cell carcinoma about to start first-line immunotherapy (ICI + ICI or ICI + TKI); Patients able to comply with the study procedures; Patients who give written informed consent personally or through a witness (study participation and data processing), before any study-specific procedure is started.

Exclusion: Previous neoplasms; Previous antineoplastic treatments; Previous steroid treatments; Active viral infections (e.g., HCV, HIV, etc.); Lack of autonomy in adhering to study procedures.

ClinicalTrials.gov NCT07018037